doi: 10.1016/j.bbapap.2017.07.003 251 XuZJinXCaiWZhouMShaoPYangZet al
Per lestimand del regime di trattamento, la variazione media del peso alla settimana 72 era del -15,0% (95% CI, -15,9 a -14,2) con una dose settimanale di 5 mg di tirzepatide, -19,5% (95% CI, -20,4 a -18,5) con una dose da 10 mg, e -20,9% (95% CI, -21,8 a -19,9) con una dose da 15 mg e -3,1% (95% CI, -4,3 a -1,9) con placebo (Figura 1A e Tabella 2)
Clinical evidence shows that Ozempic promotes dose-dependent weight loss when combined with lifestyle changes
[DOI] [PubMed] [Google Scholar] 26.Kosiborod MN, Petrie MC, Borlaug BA
Medications like Ozempic, Wegovy, and Rybelsus are brand names for a class of drugs known as GLP-1 agonists
Biosimilar risk is about molecule + label + indication Biosimilar launch risk is governed by: Residual patents that cover molecule and/or clinical use Exclusivity periods tied to reference product approvals Jurisdiction-specific rules on interchangeability and substitution Small-molecule generic risk is about Orange Book patent mapping Generic entry risk is driven by: Whether Paragraph IV certifications can be made on a legally defensible non-infringement or invalidity position Whether stays and settlements delay launch Strategic implication: Lillys risk is bifurcated: insulin and select biologics face biosimilar ramp risk, while GLP-1 and other small molecules face Orange Book and method-of-use mapping risk
